FI911986A0 - Farmaceutiska foereningar. - Google Patents

Farmaceutiska foereningar.

Info

Publication number
FI911986A0
FI911986A0 FI911986A FI911986A FI911986A0 FI 911986 A0 FI911986 A0 FI 911986A0 FI 911986 A FI911986 A FI 911986A FI 911986 A FI911986 A FI 911986A FI 911986 A0 FI911986 A0 FI 911986A0
Authority
FI
Finland
Prior art keywords
pharmaceutical form
methyl
thieno
piperazinyl
disorders
Prior art date
Application number
FI911986A
Other languages
English (en)
Other versions
FI101379B (fi
FI101379B1 (fi
FI911986A (fi
Inventor
Jiban Kumar Chakrabarti
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI911986(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI911986A0 publication Critical patent/FI911986A0/fi
Publication of FI911986A publication Critical patent/FI911986A/fi
Priority to FI971316A priority Critical patent/FI971316A0/fi
Application granted granted Critical
Publication of FI101379B publication Critical patent/FI101379B/fi
Publication of FI101379B1 publication Critical patent/FI101379B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
FI911986A 1990-04-25 1991-04-24 Menetelmä terapeuttisesti käyttökelpoisen 2-metyyli-10-(4-metyyli-1-piperatsinyyli)-4H-tieno[2,3-b][1,5]bentsodiatsepiinin valmistamiseksi FI101379B1 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI971316A FI971316A0 (fi) 1990-04-25 1997-03-27 Farmaseuttinen yhdiste

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9009229 1990-04-25
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds

Publications (4)

Publication Number Publication Date
FI911986A0 true FI911986A0 (fi) 1991-04-24
FI911986A FI911986A (fi) 1991-10-26
FI101379B FI101379B (fi) 1998-06-15
FI101379B1 FI101379B1 (fi) 1998-06-15

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911986A FI101379B1 (fi) 1990-04-25 1991-04-24 Menetelmä terapeuttisesti käyttökelpoisen 2-metyyli-10-(4-metyyli-1-piperatsinyyli)-4H-tieno[2,3-b][1,5]bentsodiatsepiinin valmistamiseksi

Country Status (33)

Country Link
EP (1) EP0454436B1 (fi)
JP (1) JP2527860B2 (fi)
KR (1) KR100195566B1 (fi)
CN (1) CN1028429C (fi)
AT (1) ATE127804T1 (fi)
AU (1) AU643267B2 (fi)
BG (1) BG61710B2 (fi)
CA (1) CA2041113C (fi)
CY (1) CY1900A (fi)
CZ (1) CZ279937B6 (fi)
DE (3) DE69112895T4 (fi)
DK (1) DK0454436T3 (fi)
ES (1) ES2078440T3 (fi)
FI (1) FI101379B1 (fi)
GB (1) GB9009229D0 (fi)
GE (1) GEP20032965B (fi)
GR (1) GR3017877T3 (fi)
HK (1) HK87596A (fi)
HU (2) HU212416B (fi)
IE (1) IE68401B1 (fi)
IL (2) IL97912A (fi)
LU (2) LU90009I2 (fi)
LV (1) LV10262B (fi)
MX (1) MX173791B (fi)
NL (2) NL970015I2 (fi)
NO (3) NO178766C (fi)
NZ (1) NZ237932A (fi)
PT (1) PT97446B (fi)
RU (1) RU2043992C1 (fi)
SI (1) SI9110739A (fi)
SK (1) SK279196B6 (fi)
YU (1) YU48049B (fi)
ZA (1) ZA913085B (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
ES2153373T3 (es) * 1992-05-29 2001-03-01 Lilly Co Eli Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
EP0828494B1 (en) * 1995-05-30 2002-07-17 Eli Lilly And Company Method for treating cognitive dysfunction
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
CA2240836A1 (en) * 1995-12-21 1997-07-03 Pierre Van Tran Method for treating dermatitis
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
WO1998011893A1 (en) 1996-09-23 1998-03-26 Eli Lilly And Company Olanzapine dihydrate d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
ATE244245T1 (de) * 1997-09-02 2003-07-15 Mitsubishi Pharma Corp Kondensierte thiophenderivate und ihre medizinische anwendung
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
NZ503641A (en) * 1997-09-30 2002-09-27 Lilly Co Eli Sustained release formulation of olanzapine pamoate suitable for treating psychotic patients
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
JP2004507548A (ja) 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
US6906062B2 (en) * 2001-12-24 2005-06-14 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
WO2003101997A1 (en) * 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
US20040063694A1 (en) * 2002-06-05 2004-04-01 Browder Monte R. Compound useful for the treatment of CNS disorders
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) * 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
PT1611139E (pt) 2003-12-22 2008-07-17 Teva Pharma Métodos de preparação de olanzapina
WO2005070939A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Synthesis of olanzapine and intermediates thereof
DE602005027308D1 (de) 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Improved processes for the synthesis of olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (en) 2011-02-14 2012-08-15 Labtec GmbH Rapidly disintegrating oral film formulation for Olanzapin
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
WO2014021804A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. A method for increasing meat and milk production
EP2879518A1 (en) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. Use of olanzapine in animals
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
PT97446B (pt) 1997-07-31
IL112575A0 (en) 1995-05-26
IL97912A (en) 1995-10-31
BG61710B2 (bg) 1998-03-31
FI101379B (fi) 1998-06-15
NL970015I2 (nl) 1997-09-01
FI101379B1 (fi) 1998-06-15
JPH0789965A (ja) 1995-04-04
KR100195566B1 (ko) 1999-06-15
LU90869I2 (fr) 2002-02-21
MX173791B (es) 1994-03-25
LV10262B (en) 1995-04-20
NO1997005I1 (no) 1997-05-12
NO178766C (no) 1996-05-29
CN1028429C (zh) 1995-05-17
CN1056693A (zh) 1991-12-04
IE911348A1 (en) 1991-11-06
CZ279937B6 (cs) 1995-09-13
IL97912A0 (en) 1992-06-21
DE69112895T2 (de) 1996-03-07
ATE127804T1 (de) 1995-09-15
CA2041113A1 (en) 1991-10-26
JP2527860B2 (ja) 1996-08-28
NO911624D0 (no) 1991-04-24
AU7518691A (en) 1991-11-07
RU2043992C1 (ru) 1995-09-20
CY1900A (en) 1991-04-24
ZA913085B (en) 1992-12-30
DK0454436T3 (da) 1995-11-13
GEP20032965B (en) 2003-05-12
SK279196B6 (sk) 1998-07-08
ES2078440T3 (es) 1995-12-16
KR910018387A (ko) 1991-11-30
PT97446A (pt) 1992-01-31
YU48049B (sh) 1996-10-18
IE68401B1 (en) 1996-06-12
NO2001028I1 (no) 2002-01-28
NL300078I1 (nl) 2002-03-01
LV10262A (lv) 1994-10-20
CA2041113C (en) 1998-07-14
GR3017877T3 (en) 1996-01-31
SI9110739A (en) 1997-10-31
EP0454436B1 (en) 1995-09-13
YU73991A (sh) 1994-01-20
DE69112895D1 (de) 1995-10-19
DE19675046I2 (de) 2001-05-23
MX25502A (es) 1993-10-01
HU911372D0 (en) 1991-10-28
GB9009229D0 (en) 1990-06-20
NL970015I1 (nl) 1997-06-02
HK87596A (en) 1996-05-24
HU211575A9 (en) 1995-12-28
DE69112895T4 (de) 2009-11-12
HUT60503A (en) 1992-09-28
AU643267B2 (en) 1993-11-11
HU212416B (en) 1996-06-28
CS9101168A2 (en) 1991-12-17
NO178766B (no) 1996-02-19
EP0454436A1 (en) 1991-10-30
FI911986A (fi) 1991-10-26
NZ237932A (en) 1993-08-26
NO911624L (no) 1991-10-28
LU90009I2 (fr) 1997-01-31

Similar Documents

Publication Publication Date Title
FI911986A (fi) Farmaceutiska foereningar.
TW372872B (en) Thieno[1,5]benzodiazepine use
KR900009625A (ko) 피리미딘류 및 그의 약리학적으로 허용되는 염류 및 그 용도
FI950909A (fi) Rasvahappojohdannaisia
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
PT935598E (pt) Derivados de 3-oxo-pirido (1,2-a)benzimidazole-4-carboxamida alquilo substituidos contendo 5 heteroatomos uteis no tratamento de disturbios do sistema nervoso central
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ELI LILLY AND COMPANY LIMITED

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L140

Extension date: 20110926

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20010020

FD Application lapsed
SPCL Withdrawal, rejection or dismissal of a supplementary protection certificate

Spc suppl protection certif: L20010020